Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 28, 2026 | Aghazadeh Behzad | Director, 10% Owner | Buy (P) | 8K | $144K |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% Owner | Buy (P) | 333K | $5.0M |
| Jul 27, 2026 | GORDON CARL L | Director | Buy (P) | 1.0M | $15.0M |
| Jul 27, 2026 | ORBIMED ADVISORS LLC | Director | Buy (P) | 1.0M | $15.0M |
| Jul 24, 2026 | Aghazadeh Behzad | Director, 10% Owner | Buy (P) | 50K | $1.1M |
| Jul 24, 2026 | Aghazadeh Behzad | Director, 10% Owner | Buy (P) | 2.3M | $35.0M |
| Jul 23, 2026 | Lucas Svetlana | Chief Business Officer | Buy (P) | 3K | $45K |
| Jul 23, 2026 | Parrot David | Chief Financial Officer | Buy (P) | 1K | $20K |
| Jul 23, 2026 | Parrot David | Chief Financial Officer | Buy (P) | 1K | $20K |
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/SCTX/capital-change-brief"
Use Arkolith's capital_change_brief for Scribe Therapeutics, Inc.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for SCTX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.